CANNEX CAPITAL HOLDINGS INC Inactive Instrument
Cannex Capital Holdings Inc Share Price Canadian Securities Exchange
Equities
CA13768L1085
Pharmaceuticals
| Sales 2024 * | 120M 165M 9.59B | Sales 2025 * | - | Capitalization | 106M 147M 8.53B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.89 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cannex Capital Holdings Inc
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 38 | - | |
Andrew Thut
CEO | Chief Executive Officer | 50 | 30/09/14 |
Karl Chowscano
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rob Hunt
CHM | Chairman | 51 | 11/04/22 |
Anthony Dutton
PRN | Corporate Officer/Principal | 66 | - |
Chetan Gulati
BRD | Director/Board Member | 46 | 30/11/20 |
4Front Ventures Corp. is a Canada-based company that is engaged in the cannabis business. The Company's capabilities include cultivation, extraction and production, packaging and distribution, and retail. The Company owns, operates or manages approximately six cultivation and production facilities and approximately 11 retail facilities across eight states.
Sector
Pharmaceuticals
Calendar
19/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +39.33% | 6.11B | |
| -18.38% | 4.35B | |
| -9.17% | 3.18B | |
| +3.98% | 3.16B | |
| -3.41% | 2.51B | |
| +48.74% | 1.98B | |
| -4.82% | 1.74B | |
| -1.24% | 1.63B | |
| -8.96% | 1.6B |
